Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Trying for a BRAF Slam Dunk

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0231Source: DataRank Database

Trying for a BRAF Slam Dunk is a research paper published in Cancer Discovery (2020). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (19 grants)Impact (FWCI 0.22)OA: bronzeTopics (38)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Roger S. Lo ORCID,Antoni Ribas ORCID

Live enrichment

PubMed:32357967 PMC:PMC7363198 OpenAlex:https://openalex.org/W3022459121

NIH

Grant: R35 CA197633

NIH

Grant: P01 CA244118

NIH

Grant: P30 CA016042

NIH

Grant: R01CA176111

NIH

Grant: R21CA215910-01

NCI NIH HHS

Grant: K22 CA151638

NCI NIH HHS

Grant: P01 CA168585

NCI NIH HHS

Grant: U54 CA199090

NCI NIH HHS

Grant: P50 CA086306

NCI NIH HHS

Grant: R01 CA170689

NCI NIH HHS

Grant: R21 CA215910

National Institutes of Health

Grant: 2R35CA197633-08

Next Generation Cancer Immunotherapies to Defeat Melanoma

National Institutes of Health

Grant: 1R21CA215910-01A1

Exploiting Drug Addiction to Improve the Efficacy of MAPK Pathway Targeted Therapy in BRAF and NRAS Mutant Melanoma

National Institutes of Health

Grant: 1P01CA244118-01A1

Combination Therapies to Defeat Melanoma Resistance

National Institutes of Health

Grant: 5R01CA176111-09

Combinatorial Targeting of Epigenomic and Microenvironmental Pathways to Suppress MAPK Inhibitor Resistance in Melanoma

National Institutes of Health

Grant: 3P30CA016042-35S3

Cancer Center Support Grant

Ressler Family Fund

American Skin Association

Parker Institute for Cancer Immunotherapy

FWCI

0.22

Citation Percentile

0.5%

Citation Trend

2020

2022

2023

bronze

journalhttps://cancerdiscovery.aacrjournals.org/content/candisc/10/5/640.full.pdf

publisherhttps://cancerdiscovery.aacrjournals.org/content/candisc/10/5/640.full.pdf

publisherhttps://aacrjournals.org/cancerdiscovery/article-pdf/10/5/640/1813711/640.pdf

journalhttps://doi.org/10.1158/2159-8290.cd-20-0231

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32357967

Fields of Study

Melanoma and MAPK PathwaysComputational Drug Discovery MethodsCytokine Signaling Pathways and Interactions0301 basic medicine0303 health sciences03 medical and health sciences0302 clinical medicineHumansMutationNeoplasmsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafVemurafenib

MeSH Terms

VemurafenibHumansMutationNeoplasmsProtein Kinase InhibitorsProto-Oncogene Proteins B-raf

Keywords

Computational biologyComputer scienceVirologyBiologyProto-Oncogene Proteins B-rafBiomedical and Clinical SciencesOncology and CarcinogenesisHuman Genome610Cancer GenomicsGood Health and Well BeingVemurafenibBiochemistry and cell biologyNeoplasmsMutationGeneticsHumansProtein Kinase InhibitorsCancer

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being